Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Details werden geladen...

https://www.manilatimes.net/2026/07/28/tmt-newswire/globenewswire/organogenesis-announces-publication-of-peer-reviewed-clinical-trial-results-demonstrating-clinical-benefit-of-affinity-in-the-most-challenging-and-complex-venous-leg-ulcers/2392505

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers | The Manila Times

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal of Wound Care demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two wound duration strata studied, providing compelling new peer-reviewed evidence for one of the most difficult-to-treat wound populations in chronic wound care.

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial | ...

https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/mdxhealth-announces-peer-reviewed-publication-of-oxford-gps-prompt-study-in-european-urology-oncology-establishing-scientific-foundation-for-the-landmark-gps-protect-randomized-controlled-trial/2374830

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma | The Manila Times

https://www.manilatimes.net/2026/07/09/tmt-newswire/globenewswire/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-deltex-dri-doubles-progression-free-survival-in-newly-diagnosed-glioblastoma/2381560

HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open | The Manila Times

https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/hmnc-brain-health-announces-publication-of-ketabon-ket01-clinical-trial-results-in-jama-network-open/2379752

Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP® | The Manila Times

https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/applied-biologics-announces-completion-of-planned-enrollment-activities-in-the-campx-randomized-controlled-trial-evaluating-xwrap/2367779

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times

https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706

MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia | The Manila Times

https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/medipharm-labs-announces-positive-phase-ii-libby-trial-results-demonstrating-significant-reduction-in-agitation-associated-with-advanced-alzheimers-disease-and-dementia/2384157

Registrieren